Registered outcomes15

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 15 of 15

List	Outcome	Time frame
Primary	AE and SAE occurrence and frequency in phase Ⅰb	Up to 2 years
Primary	Dose-limiting toxicities (DLT)	Cycle 1 (Up to 21 days)
Primary	Maximum tolerated dose (MTD)	Cycle 1 (Up to 21 days)
Primary	Recommended phase 2 dose (RP2D)	Cycle 1 (Up to 21 days)
Primary	Overall response rate (ORR) in phase Ⅱ	Up to 2 years
Secondary	Overall response rate (ORR) in phase Ⅰb	Up to 2 years
Secondary	Disease Control Rate (DCR)	Up to 2 years
Secondary	Duration of Response (DOR)	Up to 2 years
Secondary	Progression-free Survival (PFS)	Up to 2 years
Secondary	Overall survival (OS)	Up to 2 years
Secondary	AE and SAE occurrence and frequency in phase Ⅱ	Up to 2 years
Secondary	Area under the plasma concentration versus time curve (AUC)	Up to 2 years
Secondary	Peak Plasma Concentration (Cmax)	Up to 2 years
Secondary	Peak time (Tmax)	Up to 2 years
Secondary	Terminal half-life (t½)	Up to 2 years

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT05625919/registered